GeparOLA: A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel/carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients (pts) with HER2-negative early breast cancer (BC) and homologous recombination deficiency (HRD).

A. Fasching, Peter; Jackisch, Christian; Rhiem, Kerstin; Schneeweiß, Andreas; Klare, Peter; Hanusch, Claus; Huober, Jens; Link, Theresa; Untch, Michael; Schmatloch, Sabine; Denkert, Carsten; Stefek, Andrea; Uleer, Christoph; Doering, Gabriele; Engels, Knut; Seither, Fenja; Blohmer, Jens‐Uwe; Loibl, Sibylle

doi:10.1200/jco.2019.37.15_suppl.506

Public

GeparOLA: A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel/carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients (pts) with HER2-negative early breast cancer (BC) and homologous recombination deficiency (HRD).

Published in Journal of Clinical Oncology • May 20, 2019

Authors:

Peter A. Fasching

Christian Jackisch

Kerstin Rhiem

Abstract

506 Background: The efficacy and toxicity of olaparib in early BC pts with homologous DNA repair deficiency (here defined as HRD score high tumors +/- germline (g) or tumor (t) BRCA mutation) is not well described. GeparOLA investigates olaparib in HER2 negative early BC with HRD. Methods: GeparOLA ...

Subject

Medicine

Olaparib

Carboplatin

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!